« Home | Mother’s Quest for Answers in Son’s Death Continue... » | Anthrax vaccine opponents file new lawsuit » | New agency to lead hunt for bioterrorism defenses » | Bill creating HHS bioterror research agency on Bus... » | 1918 Flu Epidemic Teaching Valuable Lessons - Acti... » | Rogers' biodefense bill clears Congress » | PRESS RELEASE: NEW LAWSUIT FILED CHALLENGING LEGAL... » | Defense Employees Set For Another Suit to Halt Man... » | Trust but verify » | Law Passes Retooling Effort on Bioterror »

Md. biotech delivers doses of anthrax vaccine to HHS

Washington Business Journal, by Neil Adler, Staff Reporter

Emergent BioSolutions, which sells the only vaccine to protect against anthrax that is licensed by the Food and Drug Administration, says it has completed the delivery of more than 3 million doses of the vaccine to the Department of Health and Human Services.

The roughly 3 million doses, representing revenue of about $75 million to the company, are part of a $120 million contract awarded in May of this year by HHS to Gaithersburg-based Emergent for 5 million doses, to be delivered by May 31, 2007, that will go into the country's strategic national stockpile.

Under this contract, Emergent has delivered about 4 million doses and expects to supply the balance during the first quarter of next year, the company says.

In total, Emergent now has supplied more than 9 million doses of the vaccine, called BioThrax, to HHS. The company won a $123 million contract in May 2005 to supply an initial 5 million doses.

Emergent (NYSE: EBS), which recently went public with its stock, is competing with a handful of biotech and pharmaceutical companies developing anthrax drugs and vaccines for the U.S. government. These competitors include Rockville-based Human Genome Sciences (NASDAQ: HGSI).